Article
Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation.
Oncotarget - 1 Jan 2022
Demes Melanie, Pession Ursula, Jeroch Jan, Schulze Falko, Eichler Katrin, Martin Daniel, Wild Peter, Waidmann Oliver
Abstract excerpt
Anal cancer is a rare disease with increasing incidence. In patients with locally recurrent or metastatic disease which cannot be treated with chemoradiotherapy or salvage surgery systemic first-line chemotherapy with carboplatin and paclitaxel is standard of care. For patients who progress after first-line therapy and are still eligible for second-line therapy Programmed cell death protein 1 (PD-1) antibodies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.